INVENTIONS FOR LICENSE
MCL 1668.0: Disease Diagnosis: Method for Assessing Cortical Response to Blue Light
Perry Renshaw, M.D., Ph.D., et al.
- Diagnosis of Parkinson's Disease
- Diagnosis of Schizophrenia
- Diagnosis of Attention Deficit Disorder
Background and Description
The present invention is based on the fact that changes in CNS neurotransmitter function may occur in conjunction with changes in visual system processing. The invention makes use of blood oxygen level dependent (BOLD) functional magnetic resonance imaging (fMRI) to measure neurophysiological changes triggered by exposure to blue light. Data supporting the invention have established a baseline for average responses in humans to blue and red light, and this allows the use of the method of the invention to assess neurotransmitter-specific changes in CNS activity that are either intrinsic to the patient or are caused by exogenous factors (e.g., administration of drugs).
Potential Commercial Uses
The method of the invention can be used to study dopamine function to study or diagnose any neurologic, psychiatric and substance abuse disorders that are associated with impaired or altered CNS dopaminergic neurotransmitter function. The patient is stimulated with blue light, and the response as measured by BOLD fMRI can be compared either to baseline average values or to the response to light of a different color. The invention may therefore lead to effective diagnostic procedures for disorders relating to the dopaminergic system, such as Parkinson's disease, schizophrenia, attention deficit hyperactivity disorder, and the effects of substance abuse.
Publication and Patent Status
McLean Hospital is the owner of issued U.S. Patent Number 6,630,127 claiming this invention. (USPTO # 6,630,127)
McLean Hospital is offering a worldwide exclusive license to this technology.
For more information, please contact:Anne Ritter, Licensing Manager
Partners Research Ventures and Licensing